This peptidic drug is coformulated with sodium N-[8-(2-hydroxybenzoyl)amino]-caprylate, a gastric absorption enhancer, to promote oral bioavailability
GLP-1 medications are FDA-approved and widely used, but like any medication, they come with important considerations
So, in summary: FOXO4-DRI appears to represent the next-generation senolytic, offering improved specificity, but it is still earlier stage than many small-molecule senolytics or repurposed drug combinations
That means conclusions about people cannot be drawn from animal data, and any claims of proven human benefit would be getting ahead of the science
Although TB-500 is banned from sports, there is no evidence linking it to muscle growth in human test subjects [23]